enow.com Web Search

  1. Ads

    related to: treatment regimen for multiple myeloma cancer life expectancy chart

Search results

  1. Results from the WOW.Com Content Network
  2. Chemotherapy regimen - Wikipedia

    en.wikipedia.org/wiki/Chemotherapy_regimen

    The term "induction regimen" refers to a chemotherapy regimen used for the initial treatment of a disease. A "maintenance regimen" refers to the ongoing use of chemotherapy to reduce the chances of a cancer recurring or to prevent an existing cancer from continuing to grow. [2]

  3. DT-PACE - Wikipedia

    en.wikipedia.org/wiki/DT-PACE

    DT-PACE refers to a chemotherapy regimen for multiple myeloma consisting of Dexamethasone, Thalidomide, Cisplatin or Platinol, Adriamycin or doxorubicin, Cyclophosphamide, and Etoposide. [ 1 ] References

  4. Multiple myeloma - Wikipedia

    en.wikipedia.org/wiki/Multiple_myeloma

    Multiple myeloma is the second-most prevalent blood cancer (10%) after non-Hodgkin's lymphoma. [154] It represents about 1.8% of all new cancers and 2.1% of all cancer deaths. [7] Multiple myeloma affects slightly more men than women.

  5. Category : Chemotherapy regimens used in multiple myeloma

    en.wikipedia.org/wiki/Category:Chemotherapy...

    Pages in category "Chemotherapy regimens used in multiple myeloma" The following 2 pages are in this category, out of 2 total.

  6. Bortezomib - Wikipedia

    en.wikipedia.org/wiki/Bortezomib

    Bortezomib, sold under the brand name Velcade among others, is an anti-cancer medication used to treat multiple myeloma and mantle cell lymphoma. [4] This includes multiple myeloma in those who have and have not previously received treatment. [3] It is generally used together with other medications. [3] It is given by injection. [4]

  7. Myeloproliferative neoplasm - Wikipedia

    en.wikipedia.org/wiki/Myeloproliferative_neoplasm

    Tyrosine kinase inhibitors like imatinib have improved the prognosis of CML patients to near-normal life expectancy. [14] Recently, a JAK2 inhibitor, namely ruxolitinib, has been approved for use in primary myelofibrosis. [15] Trials of these inhibitors are in progress for the treatment of the other myeloproliferative neoplasms.

  1. Ads

    related to: treatment regimen for multiple myeloma cancer life expectancy chart